Sep 18, 2024, 22:50
Kimryn Rathmell: Tovorafenib has been approved for kids and teens who have low-grade glioma
Kimryn Rathmell shared a post on X:
“Recent Childhood Cancer breakthrough: Tovorafenib (Ojemda) has been approved for kids and teens who have low-grade glioma with changes in the BRAF gene.
In a small clinical trial, the drug shrank or eliminated tumors in nearly 70% of patients.”
Read further.
Source: Kimryn Rathmell/LinkedIn
Dr. Kimryn Rathmell serves as the director of the National Cancer Institute. She is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers.
She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19